X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CIP-137401 is a small molecule allosteric inhibitor of MEK 1/2, a key kinase in the Ras-Raf-MEK-ERK signaling pathway. Existing MEK inhibitors are marketed for a range of diseases, providing evidence for the value of regulating MEK as a drug target.
Lead Product(s): CIP-137401
Therapeutic Area: Genetic Disease Product Name: CIP-137401
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Camac Partners
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 13, 2022
Details:
AlloMek’s lead drug, CIP-137401, is a macrocyclic MEK kinase inhibitor with excellent pharmacokinetics and a profile optimized for potency and safety. The U.S. FDA has granted orphan-drug designation to CIP-137401, for the treatment of Neurofibromatosis type 1 (NF1).
Lead Product(s): CIP-137401
Therapeutic Area: Genetic Disease Product Name: CIP-137401
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
